抗Tac单抗的药效学、药代动力学及临床疗效
杨惠娣，曹惠明
[摘要] 重组人源化单克隆抗体抗Tac单抗是一种免疫抑制剂，特异性抑制T细胞介导的免疫反应，用于减少肾移植患者发生的急性排异反应。抗Tac单抗单用或联合用药均显示较好的临床疗效及耐受性。
[关键词] 抗Tac单抗；药效学；药代动力学；临床疗效
Pharmacodynamic, Pharmacological and Clinical use of Zenapax
Yang HuiDi , Chao HuiMing
[Abstract] Zenapax, recombinant humanized IgG anti-Tac monoclonal antibody, is a new immuno-suppressive drug. The compound selectively targets activated T-lymphocytes, which are known to play a pivotal role to reduce acute organ rejection in patients receiving renal transplants. Anti-Tac monoclonal antibody displayed a satisfactory clinical effect and tolerance.
[Key words] Zenapax ; Pharmacodynatics ; Pharmacological ; Clinical use
[参考文献]
[1]Guex-Crosier Y, Raber J, ChanC C, et al. Humanized antibodies against the α-chain of the IL-2R receptor and against the ß chain shared by the IL-2R and IL-15 receptors in ta monkey uveitis model of autoimmune dieseases.[J]J Immunol ,1997;158:452-8
[2]Vinceni F, Lantz M,Birnbaum J,et al. A phase 1 trial of humanized.anti-interleukin 2receptor antibody in renal transplantation.Transplantation ,1997;63:33-8
[3]Savo AM,Book BK,et al. Daclizumab rapidly saturates interleukin-2 receptor-alpha on lymph node lymphocytes in children.Transplant Proc, 1999;31:1182-3
[4]Vinceti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to the prevent acute rejectionin renal transplantation. [J] N Engl J Med, 1998，338:161-165
[5]Nashan B, et al. Reduction of acute renal allograft rejection by daclizumab.Transplantation, 1999;67:110-5
[6]Ekberg H, et al. 抗Tac单抗 reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. Transplantation Proc, 1999;31:267-8
[7]Kirkman RL, et al. A phase Ι/Ц randomized double-blind placebo-controlled study of 抗Tac单抗 in combination with Cellcept, Neoral and steroids, Nutley, USA: Hoffman La Roche Inc,1998.
[8]Vincenti F, et al. Can antibody prophlaxis allow sparing of other immunosuppressives? Transplant Proc, 1999;31:1246-8
[9]Nevin T, et al. Daclizumab in pediatric renal allografts: final data. Transplantation ,1999;67:s124
[10]抗Tac单抗 product monmgraph. Basel, Switzerland:F. Hoffman-La Roche(Basel),1997., http://www.100md.com
[摘要] 重组人源化单克隆抗体抗Tac单抗是一种免疫抑制剂，特异性抑制T细胞介导的免疫反应，用于减少肾移植患者发生的急性排异反应。抗Tac单抗单用或联合用药均显示较好的临床疗效及耐受性。
[关键词] 抗Tac单抗；药效学；药代动力学；临床疗效
Pharmacodynamic, Pharmacological and Clinical use of Zenapax
Yang HuiDi , Chao HuiMing
[Abstract] Zenapax, recombinant humanized IgG anti-Tac monoclonal antibody, is a new immuno-suppressive drug. The compound selectively targets activated T-lymphocytes, which are known to play a pivotal role to reduce acute organ rejection in patients receiving renal transplants. Anti-Tac monoclonal antibody displayed a satisfactory clinical effect and tolerance.
[Key words] Zenapax ; Pharmacodynatics ; Pharmacological ; Clinical use
[参考文献]
[1]Guex-Crosier Y, Raber J, ChanC C, et al. Humanized antibodies against the α-chain of the IL-2R receptor and against the ß chain shared by the IL-2R and IL-15 receptors in ta monkey uveitis model of autoimmune dieseases.[J]J Immunol ,1997;158:452-8
[2]Vinceni F, Lantz M,Birnbaum J,et al. A phase 1 trial of humanized.anti-interleukin 2receptor antibody in renal transplantation.Transplantation ,1997;63:33-8
[3]Savo AM,Book BK,et al. Daclizumab rapidly saturates interleukin-2 receptor-alpha on lymph node lymphocytes in children.Transplant Proc, 1999;31:1182-3
[4]Vinceti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to the prevent acute rejectionin renal transplantation. [J] N Engl J Med, 1998，338:161-165
[5]Nashan B, et al. Reduction of acute renal allograft rejection by daclizumab.Transplantation, 1999;67:110-5
[6]Ekberg H, et al. 抗Tac单抗 reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. Transplantation Proc, 1999;31:267-8
[7]Kirkman RL, et al. A phase Ι/Ц randomized double-blind placebo-controlled study of 抗Tac单抗 in combination with Cellcept, Neoral and steroids, Nutley, USA: Hoffman La Roche Inc,1998.
[8]Vincenti F, et al. Can antibody prophlaxis allow sparing of other immunosuppressives? Transplant Proc, 1999;31:1246-8
[9]Nevin T, et al. Daclizumab in pediatric renal allografts: final data. Transplantation ,1999;67:s124
[10]抗Tac单抗 product monmgraph. Basel, Switzerland:F. Hoffman-La Roche(Basel),1997., http://www.100md.com